Home » Stocks » AXSM

Axsome Therapeutics, Inc. (AXSM)

Stock Price: $70.18 USD 0.42 (0.60%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $70.00 -0.18 (-0.26%) Mar 3, 7:21 PM
Market Cap 2.65B
Revenue (ttm) n/a
Net Income (ttm) -102.90M
Shares Out 37.21M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $70.18
Previous Close $69.76
Change ($) 0.42
Change (%) 0.60%
Day's Open 69.37
Day's Range 68.70 - 71.49
Day's Volume 247,314
52-Week Range 35.44 - 109.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) ...

The Motley Fool - 3 weeks ago

This company presents much more attractive prospects than the cryptocurrency.

Zacks Investment Research - 1 month ago

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Other stocks mentioned: AVXL, HOLX, MRNA, NVAX, SAVA, VIVO, VXRT
The Motley Fool - 1 month ago

While it's already made some people rich, Axsome Therapeutics is just getting started.

The Dog of Wall Street - 1 month ago

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Other stocks mentioned: JNJ, NVAX
Zacks Investment Research - 1 month ago

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

Zacks Investment Research - 1 month ago

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agita...

GlobeNewsWire - 2 months ago

ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation

GlobeNewsWire - 2 months ago

 Over 21,000 migraine attacks treated with AXS-07

Seeking Alpha - 2 months ago

The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 ...

GlobeNewsWire - 2 months ago

68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4

Zacks Investment Research - 2 months ago

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment

GlobeNewsWire - 3 months ago

R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months

Zacks Investment Research - 3 months ago

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07.

Seeking Alpha - 3 months ago

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

NEW YORK & PLEASANTON, Calif.--(BUSINESS WIRE)-- #digitalengagement--Axsome and Veeva announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™...

Other stocks mentioned: VEEV
GlobeNewsWire - 4 months ago

NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) ...

GlobeNewsWire - 4 months ago

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time

Seeking Alpha - 4 months ago

Axsome has an excellent pipeline of late stage CNS candidates. The total market opportunity of all 4 assets is nearly $8bn.

InvestorPlace - 4 months ago

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades ap...

Other stocks mentioned: MDGL, NKLA, TLRY
Seeking Alpha - 4 months ago

The Recent Sell-Off In Axsome Creates A Good Opportunity

Seeking Alpha - 5 months ago

Today, we revisit Axsome Therapeutics for an in-depth analysis.

The Motley Fool - 5 months ago

An analyst doesn't think very highly of Axsome's prospects.

GlobeNewsWire - 5 months ago

Non-dilutive committed capital extends cash runway into at least 2024

GlobeNewsWire - 5 months ago

        S ignificantly faster time to pain relief as compared to rizatriptan (p

Zacks Investment Research - 5 months ago

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

Seeking Alpha - 5 months ago

Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 5 months ago

Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021

GlobeNewsWire - 5 months ago

Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform

Forbes - 5 months ago

There was not one single catalyst causing yesterday's rally; however, there was some excitement in the market from vaccine progress, and indicators of economic recovery. For investors looking ...

Other stocks mentioned: LB, MIK, OVV, TWO
GlobeNewsWire - 5 months ago

Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)

GlobeNewsWire - 5 months ago

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CN...

Zacks Investment Research - 5 months ago

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Forbes - 5 months ago

A day after the worst single-day drop in three months, equity markets are wavering between plunging into a deeper sell-off or recouping their losses. For investors who anticipate that this wav...

Other stocks mentioned: AAL, BYND, GT, WDC
GlobeNewsWire - 6 months ago

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CN...

GlobeNewsWire - 6 months ago

    Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS...

Zacks Investment Research - 6 months ago

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

GlobeNewsWire - 6 months ago

 NDA submission on track for 4Q 2020

Zacks Investment Research - 6 months ago

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

The Motley Fool - 6 months ago

The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.

Seeking Alpha - 6 months ago

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020

Seeking Alpha - 6 months ago

Axsome Therapeutics: Big Unfolding Catalyst

GlobeNewsWire - 7 months ago

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time

Seeking Alpha - 7 months ago

The Secondary Impact Of COVID-19 Pandemic Leads To Bigger Market Potential For Axsome Therapeutics

Zacks Investment Research - 7 months ago

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.

GlobeNewsWire - 7 months ago

 NDA submission on track for 4Q 2020

About AXSM

Axsome Therapeutics, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 19, 2015
CEO
Herriot Tabuteau
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
AXSM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 143.85, which is an increase of 104.97% from the latest price.

Price Target
$143.85
(104.97% upside)
Analyst Consensus: Strong Buy